Carlsmed (CARL) investor relations material

Key financial and operational highlights

• Achieved $15M+ in Q4 revenue with 76.5% gross margin and 61% YoY quarterly growth.

• Full-year revenue reached $50.5M, representing 86% YoY growth; guidance for 2024 is $70M–$75.5M.

• User base grew by nearly 70%, ending the year with 253 trained surgeon users.

• Strong cash position post-IPO provides runway to cash flow break-even.

• Commercial model leverages both direct and distributor sales for rapid adoption.

Technology and clinical innovation

• The aprevo® platform enables personalized, 3D-modeled surgical plans and devices for spine fusion.

• Two-year data published in Global Spine Journal showed a 74% reduction in revision rates versus traditional procedures.

• Digital production system delivers sterile-packed, patient-specific devices within eight business days.

• Post-op data collection and feedback loop continuously improve the platform's personalization.

• Devices are 3D-printed from porous titanium alloy for optimal osseointegration.

Market expansion and reimbursement

• U.S. addressable market exceeds 800,000 spine fusion procedures annually.

• Expanded from lumbar to cervical spine with new platform launches, targeting high-revision patient populations.

• Achieved Breakthrough Device Designation and New Technology Add-on Payments for both lumbar and cervical platforms.

• Permanent DRGs for lumbar fusion technology implemented in late 2024, incentivizing hospital adoption.

• Cervical platform provides $21,000+ incremental reimbursement per procedure.